Document is current

Article History

Received: 13 March 2022

Accepted: 11 July 2022

First Online: 17 October 2022

Declarations

:

: Ethical approval was provided by the Royal Brisbane & Women’s Hospital Human Research Ethics Committee (LNR/2020/QRBW/69723). A statement at the start of the survey (see Supplementary data) informed the participant that if they proceeded to complete the survey we would take this as informed consent to participate. This approach to consenting participants was approved by Royal Brisbane & Women’s Hospital Human Research the ethics committee, therefore we did not seek or obtain written informed consent. All methods were performed in accordance with the relevant guidelines and regulations.

: Not required.

: JT: None. DFL: None. CA: None. RB: RB reports no conflicts of interest. CH: CH reports no personal fees and grant funding from Vifor Pharmaceuticals. CH reports speaking at Janssen symposium with no personal fees. SP: SP reports personal fees from Janssen and Boehringer-Ingelheim and grant funding from Janssen and Glaxo Smith Kline. SW: SW reports no conflicts of interest. PCR: PR reports personal fees from Abbvie, Atom Biosciences, Eli Lilly, Gilead, Janssen, Novartis, UCB, Roche, Pfizer; meeting attendance support from BMS, Eli Lilly, Pfizer and UCB Pharma and grant funding from Janssen, Novartis, Pfizer and UCB Pharma.